RCRC
15.10.2019 16:51:08 CEST | Business Wire | Press release
The Royal Commission for Riyadh City (RCRC), formally known as Riyadh Development Authority, has invited international experts to participate in a Symposium setting out the next chapter in Riyadh’s development as a sustainable city, one that will enhance the lives of its citizens, while finding solutions to the difficult challenges facing all cities across the world today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005797/en/
‘Riyadh’s Sustainable Future’ Symposium will take place on November 12 & 13, 2019 in Riyadh and will focus on four of the capital’s most ambitious projects, launched by King Salman bin Abdulaziz Al Saud, and stemming from an initiative from Prince Mohammed bin Salman bin Abdulaziz Al Saud, the Crown Prince.
These four projects are transformative and will help to establish Riyadh as one of the most livable cities in the world.
King Salman Park (www.riyadhksp.sa/en/ ) promises to be the largest green city park in the world; Sports Boulevard (www.riyadhalmasar.sa/en/ ) will be a state-of-the-art new health and wellness destination in the heart of the city; Green Riyadh (www.riyadhgreen.sa/en/ ) will focus on planting 7.5 million trees all over the city; and Riyadh Art (www.riyadhart.sa/en/ ) will delight art lovers with its 1,000 curated art pieces, iconic installations and annual arts festival through its world-class interactive public arts program.
The Symposium will invite discussion across a variety of subject areas, including climate change; sustainable urban development; conservation of the natural environment; critical resource management; energy conservation, production and management; legal frameworks and initiatives to support positive change; and transformative social activation.
The four projects complement Saudi Vision 2030’s ‘Quality of Life’ Program and are aligned with the U.N. Sustainable Development Goals, to create sustainable cities and communities, while driving urgent action against climate change.
Professor David Griggs, an expert in sustainable city planning, who will be attending the Symposium, commented: “The challenge of transforming a rapidly growing city in the desert into a sustainable, responsible, and inspiring place to live is enormous. The world’s largest urban parks, 7.5 million trees to green the city, a 135 km sports corridor and more than 1,000 pieces of public art, are just four of the projects that will transform the city. The ‘Riyadh’s Sustainable Future’ Symposium will bring together some of the world’s leading experts to provide their wisdom and advice for these projects and, in doing so, help Riyadh towards a future its citizens and the world can be proud of.”
For Riyadh and its citizens, the ultimate goal is to create a more sustainable city and a thriving, active community in the long term, while acting against climate change concerns. This Symposium is an important step in achieving that goal.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005797/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom